Aditya Birla Sun Life Pharma & Healthcare Fund Regular-Growth
The fund is rated 2 stars. The strongest area was balance between returns and downside risk, while investment selection within each industry provided some support. Investment selection within each asset type did not provide enough support for a higher rating. Higher annual fee of 2.29% was a minor drawback.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a good risk-reward ratio. It is important to note, however, that this fund has a 1102.73 AUM and a 2.29 expense ratio. Considering all these factors, we have rated this fund as 2.0 star.
आमचा स्कोअर दीर्घकालीन कामगिरी, जोखीम आणि सातत्य यांचे वजन करतो — फक्त मागील परतावे नाही.
परतावा
8 Oct 2026 पर्यंत
जोखीम गुणोत्तरे
30 Sep 2026 पर्यंत
पोर्टफोलिओ
30 Sep 2026 पर्यंत
मार्केट-कॅप विभागणी
क्षेत्रनिहाय वाटप
होल्डिंग्स (40)
| होल्डिंग | फंडाचा % | मूल्य | शेअर्स |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd. | 9.28% | ₹99.97 Cr | 2,08,262 |
| Sun Pharmaceutical Industries Ltd. | 8.61% | ₹92.79 Cr | 5,10,815 |
| Apollo Hospitals Enterprise Ltd. | 6.44% | ₹69.35 Cr | 84,936 |
| Cipla Ltd. | 6.38% | ₹68.71 Cr | 5,10,452 |
| Aurobindo Pharma Ltd. | 4.52% | ₹48.7 Cr | 2,91,254 |
| Sai Life Sciences Ltd. | 4.49% | ₹48.36 Cr | 3,17,245 |
| Ajanta Pharma Ltd. | 4.34% | ₹46.82 Cr | 1,29,312 |
| Mankind Pharma Ltd. | 3.62% | ₹38.95 Cr | 1,55,574 |
| Dr. Lal Pathlabs Ltd. | 3.50% | ₹37.77 Cr | 1,90,095 |
| Abbott India Ltd. | 3.25% | ₹35.08 Cr | 12,933 |
फंड तपशील
Long term capital growth. investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Exit load of 1% if redeemed within 30 days.